Literature DB >> 26787602

Radiogenomic correlation in lung adenocarcinoma with epidermal growth factor receptor mutations: Imaging features and histological subtypes.

Su Jin Hong1,2, Tae Jung Kim3,4, Yo Won Choi2, Jeong-Soo Park5, Jin-Haeng Chung6, Kyung Won Lee1.   

Abstract

OBJECTIVES: To correlate imaging features of resected lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutation and the IASLC/ATS/ERS classification histological subtypes.
METHODS: In 250 consecutive patients with resected lung adenocarcinoma, EGFR mutation status was correlated with demographics, imaging features including ground-glass opacity (GGO) proportion and the IASLC/ATS/ERS classification histological subtypes.
RESULTS: EGFR mutations were significantly more frequent in women (54.5 % vs. 38.1 %, p = 0.011) and in never-smokers (54.7 % vs. 35.3 %, p = 0.003). GGO proportion was significantly higher in tumours with EGFR mutation than in those without (30.3 ± 33.8 % vs. 19.0 ± 29.3 %, p = 0.005). EGFR mutation was significantly more frequent in tumours with GGO ≥ 50 % and tumours with any GGO (p = 0.026 and 0.008, respectively). Adenocarcinomas with exon 19 or 21 mutation showed significantly higher GGO proportion than that in EGFR wild-type tumours (p = 0.009 and 0.029, respectively). Absence of GGO was an independent predictor of negative EGFR mutation (odds ratio, 1.81; 95 % confidence interval, 1.16-3.04; p = 0.018).
CONCLUSIONS: GGO proportion in adenocarcinomas with EGFR mutation was significantly higher than that in EGFR wild-type tumours, and the absence of GGO on CT was an independent predictor of negative EGFR mutation. KEY POINTS: • Ground-glass opacity (GGO) proportion is significantly higher in EGFR-mutated adenocarcinomas • Exon 19 or 21 mutated adenocarcinomas shows significantly higher GGO proportion • GGO absence is an independent predictor of negative EGFR mutation in lung adenocarcinomas.

Entities:  

Keywords:  Adenocarcinoma; Computed tomography (CT); Epidermal growth factor receptor (EGFR); Lung; Mutation

Mesh:

Substances:

Year:  2016        PMID: 26787602     DOI: 10.1007/s00330-015-4196-z

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  29 in total

1.  Fleischner Society: glossary of terms for thoracic imaging.

Authors:  David M Hansell; Alexander A Bankier; Heber MacMahon; Theresa C McLoud; Nestor L Müller; Jacques Remy
Journal:  Radiology       Date:  2008-01-14       Impact factor: 11.105

2.  EGFR L858R mutation is associated with lung adenocarcinoma patients with dominant ground-glass opacity.

Authors:  Yong Yang; Yang Yang; Xiao Zhou; Xiao Song; Ming Liu; Wenxin He; Hao Wang; Chunyan Wu; Ke Fei; Gening Jiang
Journal:  Lung Cancer       Date:  2015-01-05       Impact factor: 5.705

3.  Epidermal growth factor receptor gene mutation and computed tomographic findings in peripheral pulmonary adenocarcinoma.

Authors:  Motoki Yano; Hidefumi Sasaki; Yoshihiro Kobayashi; Haruhiro Yukiue; Hiroshi Haneda; Eriko Suzuki; Katsuhiko Endo; Osamu Kawano; Masaki Hara; Yoshitaka Fujii
Journal:  J Thorac Oncol       Date:  2006-06       Impact factor: 15.609

4.  Proportion of ground-glass opacity on high-resolution computed tomography in clinical T1 N0 M0 adenocarcinoma of the lung: A predictor of lymph node metastasis.

Authors:  Haruhisa Matsuguma; Kohei Yokoi; Masaki Anraku; Tetsuro Kondo; Yukari Kamiyama; Kiyoshi Mori; Keigo Tominaga; Yukio Tsuura; Satoshi Honjo
Journal:  J Thorac Cardiovasc Surg       Date:  2002-08       Impact factor: 5.209

5.  Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients.

Authors:  Akihiko Yoshizawa; Shinji Sumiyoshi; Makoto Sonobe; Masashi Kobayashi; Masakazu Fujimoto; Fumi Kawakami; Tatsuaki Tsuruyama; William D Travis; Hiroshi Date; Hironori Haga
Journal:  J Thorac Oncol       Date:  2013-01       Impact factor: 15.609

6.  Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib.

Authors:  Vincent A Miller; Gregory J Riely; Maureen F Zakowski; Allan R Li; Jyoti D Patel; Robert T Heelan; Mark G Kris; Alan B Sandler; David P Carbone; Anne Tsao; Roy S Herbst; Glenn Heller; Marc Ladanyi; William Pao; David H Johnson
Journal:  J Clin Oncol       Date:  2008-03-20       Impact factor: 44.544

Review 7.  Radiologic implications of the 2011 classification of adenocarcinoma of the lung.

Authors:  John H M Austin; Kavita Garg; Denise Aberle; David Yankelevitz; Keiko Kuriyama; Hyun-Ju Lee; Elisabeth Brambilla; William D Travis
Journal:  Radiology       Date:  2012-10-15       Impact factor: 11.105

8.  Advanced lung adenocarcinoma harboring a mutation of the epidermal growth factor receptor: CT findings after tyrosine kinase inhibitor therapy.

Authors:  Chang-Min Choi; Mi Young Kim; Jae Cheol Lee; Hwa Jung Kim
Journal:  Radiology       Date:  2013-10-28       Impact factor: 11.105

9.  Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

Authors:  Vincent A Miller; Mark G Kris; Neelam Shah; Jyoti Patel; Christopher Azzoli; Jorge Gomez; Lee M Krug; William Pao; Naiyer Rizvi; Barbara Pizzo; Leslie Tyson; Ennapadam Venkatraman; Leah Ben-Porat; Natalie Memoli; Maureen Zakowski; Valerie Rusch; Robert T Heelan
Journal:  J Clin Oncol       Date:  2004-03-15       Impact factor: 44.544

10.  Predictive value of 18F-FDG PET and CT morphologic features for recurrence in pathological stage IA non-small cell lung cancer.

Authors:  Kai-Hsiung Ko; Hsian-He Hsu; Tsai-Wang Huang; Hong-Wei Gao; Cheng-Yi Cheng; Yi-Chih Hsu; Wei-Chou Chang; Chi-Ming Chu; Jia-Hong Chen; Shih-Chun Lee
Journal:  Medicine (Baltimore)       Date:  2015-01       Impact factor: 1.889

View more
  21 in total

Review 1.  NCTN Assessment on Current Applications of Radiomics in Oncology.

Authors:  Ke Nie; Hania Al-Hallaq; X Allen Li; Stanley H Benedict; Jason W Sohn; Jean M Moran; Yong Fan; Mi Huang; Michael V Knopp; Jeff M Michalski; James Monroe; Ceferino Obcemea; Christina I Tsien; Timothy Solberg; Jackie Wu; Ping Xia; Ying Xiao; Issam El Naqa
Journal:  Int J Radiat Oncol Biol Phys       Date:  2019-01-31       Impact factor: 7.038

2.  Correlation in histological subtypes with high resolution computed tomography signatures of early stage lung adenocarcinoma.

Authors:  Yingying Miao; Jianya Zhang; Jiawei Zou; Qingqing Zhu; Tangfeng Lv; Yong Song
Journal:  Transl Lung Cancer Res       Date:  2017-02

Review 3.  Pulmonary ground-glass opacity: computed tomography features, histopathology and molecular pathology.

Authors:  Jian-Wei Gao; Stefania Rizzo; Li-Hong Ma; Xiang-Yu Qiu; Arne Warth; Nobuhiko Seki; Mizue Hasegawa; Jia-Wei Zou; Qian Li; Marco Femia; Tang-Feng Lv; Yong Song
Journal:  Transl Lung Cancer Res       Date:  2017-02

4.  Predictive models for patients with lung carcinomas to identify EGFR mutation status via an artificial neural network based on multiple clinical information.

Authors:  Xiaoyi Qin; Hailong Wang; Xiang Hu; Xiaolong Gu; Wei Zhou
Journal:  J Cancer Res Clin Oncol       Date:  2019-12-05       Impact factor: 4.553

Review 5.  Clinical and Radiological Characteristics to Differentiate Between EGFR Exon 21 and Exon 19 Mutations in Patients With Lung Adenocarcinoma: A Systematic Literature Review and Meta-Analysis.

Authors:  Andrés Felipe Herrera Ortiz; Mateo E Garland; Bassel Almarie
Journal:  Cureus       Date:  2022-05-29

6.  Epidermal growth factor receptor mutations in lung adenocarcinoma: associations between dual-energy spectral CT measurements and histologic results.

Authors:  Guojin Zhang; Junlin Zhou; Yuntai Cao; Jing Zhang; Zhiyong Zhao; Wenjuan Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2020-09-26       Impact factor: 4.553

7.  Radiomics for Classifying Histological Subtypes of Lung Cancer Based on Multiphasic Contrast-Enhanced Computed Tomography.

Authors:  Linning E; Lin Lu; Li Li; Hao Yang; Lawrence H Schwartz; Binsheng Zhao
Journal:  J Comput Assist Tomogr       Date:  2019 Mar/Apr       Impact factor: 1.826

8.  Identification of epidermal growth factor receptor mutations in pulmonary adenocarcinoma using dual-energy spectral computed tomography.

Authors:  Meng Li; Li Zhang; Wei Tang; Yu-Jing Jin; Lin-Lin Qi; Ning Wu
Journal:  Eur Radiol       Date:  2018-10-26       Impact factor: 5.315

9.  Computed tomography and clinical features associated with epidermal growth factor receptor mutation status in stage I/II lung adenocarcinoma.

Authors:  Jiawei Zou; Tangfeng Lv; Suhua Zhu; Zhenfeng Lu; Qin Shen; Leilei Xia; Jie Wu; Yong Song; Hongbing Liu
Journal:  Thorac Cancer       Date:  2017-04-06       Impact factor: 3.500

10.  Aberrant status and clinicopathologic characteristic associations of 11 target genes in 1,321 Chinese patients with lung adenocarcinoma.

Authors:  Mengnan Zhao; Cheng Zhan; Ming Li; Xiaodong Yang; Xinyu Yang; Yong Zhang; Miao Lin; Yifeng Xia; Mingxiang Feng; Qun Wang
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.